Literature DB >> 2126579

Single-compartment model analysis of thyrotropin-releasing hormone kinetics in hyper- and hypothyroid patients. Kinetic studies using a combined system of RIA and FPLC.

L Duntas1, F S Keck, J Rosenthal, C Wolf, U Loos, E F Pfeiffer.   

Abstract

The pharmacokinetics of thyrotropin-releasing hormone (TRH) were assessed following an i.v. injection in blood of ten hyperthyroid, ten hypothyroid, and six normal subjects. A single-compartment model was employed. After methanol extraction, TRH concentrations were analyzed using a specific radioimmunoassay technique combined with fast protein liquid chromatography (FPLC). As for the basal levels of TRH, no differences were observed in either study group. Peak concentrations were always present two min after the injection of TRH. In the euthyroid subjects, TRH blood levels had a half-life (t1/2) of 6.5 +/- 0.41 min, mean +/- SD, while t1/2 was 7.2 +/- 0.62 min in the hyperthyroid and t1/2 was 12 +/- 1.67 min (p less than 0.001) in the hypothyroid patients. The metabolic clearance rate (MCR) (82.2 +/- 15.3 liters/m2/day vs. 89.8 +/- 17.2) and the volume of distribution (Vd) (7.1 +/- 4.2 liters vs. 7.3 +/- 3.4) were approximately the same in the normal subjects and in the hyperthyroid group. MCR (66.2 +/- 15.3 liters/m2/day) and Vd (6.2 +/- 3.3 liters) were found to be lower in the hypothyroid patients. In FPLC, when TRH was added to plasma, it eluted in one peak. Blood samples taken 5 min after TRH i.v. injection had an elution profile of 9.94 ml. These data indicate that 1) TRH has a very short half-life, 2) hypothyroidism can prolong the t1/2 of exogenous TRH, and 3) when TRH should be used in clinical studies, the function of the thyroid gland has to be taken into consideration.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2126579     DOI: 10.1007/bf01646547

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  28 in total

1.  Effect of low intravenous doses of TRH, acid-TRH and cyclo(His-Pro) on cerebral and peripheral blood flows.

Authors:  L O Koskinen
Journal:  Br J Pharmacol       Date:  1986-03       Impact factor: 8.739

2.  "Short" loop feedback regulation of hypothalamic and brain thyrotropin-releasing hormone content in the rat and dwarf mouse.

Authors:  E Roti; D Christianson; A R Harris; L E Braverman; A G Vagenakis
Journal:  Endocrinology       Date:  1978-11       Impact factor: 4.736

3.  Thyrotropin-releasing hormone in experimental spinal injury: dose response and late treatment.

Authors:  A I Faden; T P Jacobs; M T Smith
Journal:  Neurology       Date:  1984-10       Impact factor: 9.910

4.  Effect of thyroxine on the inactivation of thyrotrophin-releasing hormone by rat and human plasma.

Authors:  A Dupont; F Labrie; L Levasseur; J H Dussault; A V Schally
Journal:  Clin Endocrinol (Oxf)       Date:  1976-07       Impact factor: 3.478

5.  The inactivation of thyrotrophin releasing hormone by plasma in thyroid disease.

Authors:  S L Jeffcoate; N White
Journal:  Clin Endocrinol (Oxf)       Date:  1975-05       Impact factor: 3.478

6.  In vitro plasma inactivation of thyrotropin releasing factor (TRF) and related peptides. Its inhibition by various means and by the synthetic dipeptide PCA-His-OME.

Authors:  W W Vale; R Burgus; T F Dunn; R Guillemin
Journal:  Hormones       Date:  1971

7.  Effect of thyroid status and paraventricular area lesions on the release of thyrotropin-releasing hormone and catecholamines into hypophysial portal blood.

Authors:  J M Rondeel; W J de Greef; P van der Schoot; B Karels; W Klootwijk; T J Visser
Journal:  Endocrinology       Date:  1988-07       Impact factor: 4.736

8.  [Pharmacokinetics and pharmacodynamics of protirelin (TRH) in man].

Authors:  L Duntas; F S Keck; U Loos; E F Pfeiffer
Journal:  Dtsch Med Wochenschr       Date:  1988-09-02       Impact factor: 0.628

9.  Serum inactivation of the immunological and biological activity of thyrotropin releasing hormone (TRH).

Authors:  R Bassiri; R D Utiger
Journal:  Endocrinology       Date:  1972-09       Impact factor: 4.736

10.  Effect on weakness and spasticity in amyotrophic lateral sclerosis of thyrotropin-releasing hormone.

Authors:  W K Engel; T Siddique; J T Nicoloff
Journal:  Lancet       Date:  1983-07-09       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.